{"product_id":"supernus-business-model-canvas","title":"Supernus Pharmaceuticals Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeted CNS therapies and strategic licensing mapped in a concise Business Model Canvas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Supernus Pharmaceuticals aligns targeted CNS therapies, strategic licensing, and focused commercialization in a concise Business Model Canvas; three to five clear sentences map value propositions, key partners, revenue streams, and cost drivers. Purchase the full Canvas to access editable Word\/Excel files and actionable strategic insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCROs \u0026amp; academic alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartnering with CROs and academic centers lets Supernus tap specialized neuroscience talent, \u0026gt;200 trial sites and patient pools, leveraging a CRO market that exceeded $60B in 2024 to accelerate CNS discovery and clinical execution. These alliances can cut recruitment-driven delays by up to 30%, lower fixed infrastructure costs through shared resources, increase trial throughput, and yield joint publications that strengthen credibility with regulators and prescribers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCMOs \u0026amp; API suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSupernus leverages CMOs for scale and complex cGMP formulations, aligning manufacturing to 21 CFR 210\/211 and PIC\/S standards to maintain quality and regulatory compliance. Reliable, qualified API suppliers stabilized supply and cost through formal supplier qualification per FDA\/EMA expectations. Robust technical transfer and process optimization reduce batch variability and ensure consistent product performance. Multiple qualified suppliers and dual-sourcing create redundancy to mitigate supply-chain risk highlighted by FDA drug shortage monitoring.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory \u0026amp; safety consultants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEngage regulatory and safety consultants to navigate FDA and EMA pathways for CNS indications, aligning with PDUFA target review windows of 6 months (priority) and 10 months (standard). Optimize trial design, endpoints and labeling strategies to reduce query rates and resubmissions. Strengthen pharmacovigilance and post-marketing safety systems to meet commitments and Risk Evaluation and Mitigation Strategy requirements. Faster approvals and fewer deficiencies protect launch timing and revenue forecasts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty pharmacies \u0026amp; distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAligning with specialty pharmacies and distributors lets Supernus delegate prior authorizations, cold-chain logistics, and adherence programs to improve patient access and speed to therapy; specialty drugs represented about 50% of U.S. drug spend in 2023 (IQVIA). Shared data builds real-world evidence and informs inventory planning while financial-assistance workflows cut abandonment and accelerate starts.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrior auths handled by specialty channels\u003c\/li\u003e\n\u003cli\u003eCold-chain + adherence programs\u003c\/li\u003e\n\u003cli\u003eRWE \u0026amp; inventory planning via data sharing\u003c\/li\u003e\n\u003cli\u003eFinancial assistance reduces abandonment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient groups \u0026amp; KOL networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborate with advocacy organizations and KOLs in neurology and psychiatry to integrate patient-reported outcomes into development, driving guideline inclusion and expanding education; epilepsy affects ~3.4 million Americans, ADHD adult prevalence ~4.4%, and Parkinson’s ~1 million in the US, focusing trust and awareness in these communities.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdvocacy + KOL engagement\u003c\/li\u003e\n\u003cli\u003ePROs in trials\u003c\/li\u003e\n\u003cli\u003eGuideline citation \u0026amp; education\u003c\/li\u003e\n\u003cli\u003eTarget: epilepsy, ADHD, Parkinson’s\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlliances speed CNS trials and secure supply; \u003cstrong\u003e$60B+\u003c\/strong\u003e CRO market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupernus partners with CROs, CMOs, API suppliers, regulators, specialty pharmacies and advocacy\/KOLs to accelerate CNS trials and secure supply. CRO market \u0026gt;$60B (2024) and dual-sourcing mitigate FDA shortage risk; PDUFA windows 6\/10 months guide regulatory timing. Specialty drugs ~50% of U.S. drug spend (2023); target pools: epilepsy 3.4M, adult ADHD 4.4%, Parkinson’s 1M.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eBenefit\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\u003c\/td\u003e\n\u003ctd\u003eTrial speed\/recruitment\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$60B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\/API\u003c\/td\u003e\n\u003ctd\u003eQuality \u0026amp; redundancy\u003c\/td\u003e\n\u003ctd\u003eDual-sourcing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty\u003c\/td\u003e\n\u003ctd\u003eAccess \u0026amp; adherence\u003c\/td\u003e\n\u003ctd\u003e50% US spend (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Supernus Pharmaceuticals outlining nine blocks—value propositions centered on specialty CNS therapies, customer segments of neurologists\/psychiatrists and payers, omni-channel commercialization and licensing partnerships, core R\u0026amp;D and regulatory capabilities, and revenue driven by branded product sales and royalties. Includes competitive advantages, partner ecosystem, cost structure, and key risks\/opportunities for strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Supernus Pharmaceuticals’ business model with editable cells, showing how its CNS-focused pipeline, specialty commercial channels, and patient support programs directly address unmet treatment pain points for patients and prescribers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeted CNS R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiscover and optimize therapies for unmet needs in epilepsy, ADHD, and Parkinson’s by advancing candidates from preclinical through Phase 3 to ensure commercial viability. Leverage formulation science to deliver controlled-release benefits that improve adherence and tolerability. Prioritize mechanisms offering differentiated efficacy or safety and maintain a balanced pipeline across risk stages to manage portfolio risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trials execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesign and run Phase I–IV studies with rigorous endpoints, typically enrolling 20–100 subjects in Phase I and 300–3,000 in Phase III to demonstrate safety and efficacy. Accelerate enrollment via specialized centers and disease registries to shorten timelines and improve recruitment diversity. Ensure demographic representativeness and regulatory compliance to strengthen labeling. Generate real-world and trial evidence to support payer value dossiers and pricing negotiations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory strategy \u0026amp; submissions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrepare INDs, NDAs\/sNDAs and manage post-approval commitments for approved assets such as Qelbree (FDA approval 2021), coordinating agency meetings and timely responses to FDA queries to preserve approval status. Align labeling to emphasize therapeutic differentiation and commercial value propositions. Maintain global readiness for ex-US filings from the Rockville, MD headquarters to support international launch opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical affairs \u0026amp; education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMedical affairs drives balanced scientific exchange and publications with HCPs, linking evidence to practice for conditions like epilepsy (≈50 million patients globally; ≈3.4 million in the US). It supports congress symposia and advisory boards, develops dosing, safety and patient-selection materials, and facilitates real-world data generation and interpretation to inform label and formulary decisions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEngage HCPs with balanced science\u003c\/li\u003e\n\u003cli\u003eSupport symposia \u0026amp; advisory boards\u003c\/li\u003e\n\u003cli\u003eDosing, safety \u0026amp; patient-selection materials\u003c\/li\u003e\n\u003cli\u003eGenerate \u0026amp; interpret RWD\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket access \u0026amp; lifecycle management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNegotiate coverage, formulary placement, and rebate contracts with payers to secure access for core CNS portfolio while implementing patient support and HUB services to reduce initiation friction and adherence barriers. Drive lifecycle management by expanding indications and geographies, and optimize pricing and contracting using real-world outcomes and HEOR data to support value-based agreements.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eNegotiation: payer coverage \u0026amp; rebates\u003c\/li\u003e\n\u003cli\u003eHUB: patient support to cut friction\u003c\/li\u003e\n\u003cli\u003eLifecycle: indication \u0026amp; geographic expansion\u003c\/li\u003e\n\u003cli\u003ePricing: outcomes-driven contracts\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvance controlled-release CNS therapies for epilepsy, ADHD and Parkinson's through rigorous trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiscover and advance CNS therapies (epilepsy, ADHD, Parkinson’s) from preclinical to Phase 3, emphasizing controlled‑release differentiation and balanced pipeline risk. Execute Phase I–IV trials with rigorous endpoints and diverse enrollment to generate label‑supporting and real‑world evidence. Manage regulatory filings (IND\/NDA\/sNDA), post‑approval commitments, medical affairs, and payer negotiations to secure access and lifecycle expansion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQelbree FDA approval\u003c\/td\u003e\n\u003ctd\u003e2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal epilepsy prevalence\u003c\/td\u003e\n\u003ctd\u003e≈50M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase III typical enrollment\u003c\/td\u003e\n\u003ctd\u003e300–3,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Business Model Canvas for Supernus Pharmaceuticals shown here is the actual deliverable, not a mockup. After purchase you'll receive this identical, fully editable document in Word and Excel with all sections and content included. No placeholders, no surprises—what you preview is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCNS-focused IP portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSupernus’ CNS-focused IP portfolio includes granted patents on molecules, formulations and delivery technologies, with U.S. patent terms up to 20 years from filing. Freedom-to-operate and regulatory exclusivity windows (Hatch‑Waxman up to 5 years, orphan 7 years, pediatric +6 months) protect margins. Trade secrets on release kinetics create further barriers to entry. Robust patents and know‑how materially strengthen partnering leverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical \u0026amp; real-world datasets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical trial datasets capture efficacy, safety, and QoL endpoints for Supernus programs, while real-world evidence from claims and EHRs supports label expansion and payer negotiations; maintained safety databases underpin continuous pharmacovigilance, and integrated data assets power predictive analytics for patient-segmentation and commercial targeting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized commercial force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupernus deploys neurology- and psychiatry-focused sales and access teams that cultivate deep relationships with KOLs and specialty treatment centers to drive adoption. Their commercial force is proficient in navigating prior authorizations and specialty distribution channels, key as specialty drugs represented about 55% of US drug spend in 2023. Continuous customer-insight loops feed field strategy and formulary\/access tactics in real time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ecGMP manufacturing network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eQualified CMOs plus Supernus internal scale-up expertise enable reliable commercial production of complex extended-release formulations.\u003c\/p\u003e\n\u003cp\u003eStringent process controls and validated unit operations ensure batch-to-batch consistency critical for ER products.\u003c\/p\u003e\n\u003cp\u003eMultiple manufacturing sites provide supply resilience and mitigate single-site disruption risk.\u003c\/p\u003e\n\u003cp\u003eRobust QC\/QA systems govern release testing, stability and regulatory compliance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQualified CMOs\u003c\/li\u003e\n\u003cli\u003eInternal scale-up know-how\u003c\/li\u003e\n\u003cli\u003eProcess controls for consistency\u003c\/li\u003e\n\u003cli\u003eMulti-site resilience\u003c\/li\u003e\n\u003cli\u003eQC\/QA supply safeguards\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital \u0026amp; partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStrong balance sheet—cash and investments ~$130M at end-2024 and available credit lines support R\u0026amp;D and launches; strategic alliances in 2024 de-risked pipelines and broadened market reach. Milestone-based payments align partner incentives, preserving upside while shifting upfront cost. Optionality retained for co-promotion or out-licensing to monetize assets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash ~130M (end-2024)\u003c\/li\u003e\n\u003cli\u003eCommitted credit lines\u003c\/li\u003e\n\u003cli\u003eMilestone-driven deals\u003c\/li\u003e\n\u003cli\u003eCo-promotion\/out-license optionality\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCNS IP, RWE-driven launches, neurology sales \u0026amp; supply; cash \u003cstrong\u003e$130M\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDeep CNS patent estate and trade secrets protect ER formulations; clinical\/RWE datasets and safety databases support label expansion and payer talks; neurology-focused sales + specialty distribution drive adoption; qualified CMOs, multi-site manufacturing and QC\/QA ensure supply; cash ~130M end-2024 and credit lines fund launches and partnerships.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003e2024 Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$130M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty sales\u003c\/td\u003e\n\u003ctd\u003eNeurology-focused\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eMulti-site, CMOs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImproved seizure control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDeliver therapies designed to reduce seizure frequency and improve daily function through consistent plasma exposure that lowers breakthrough events. Pivotal trials and real-world evidence demonstrate robust clinical outcomes with statistically significant seizure reductions and improved patient-reported functioning. Enhanced consistency builds patient and caregiver confidence in long-term seizure control.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnce-daily \u0026amp; controlled release\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFormulations designed for once-daily controlled release improve convenience and adherence; meta-analyses through 2024 show roughly 25% higher adherence versus multiple daily dosing. Smoother pharmacokinetics lower peak-driven side effects and discontinuations. Simplified regimens reduce caregiver burden and support stronger real-world effectiveness versus historical averages (WHO adherence ~50%).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient-centric support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHUB services streamline access, affordability, and adherence, often cutting benefits verification from weeks to as low as 24–48 hours and accelerating starts. Nurse educators and digital reminders boost persistence, with programs reporting persistence gains in the mid-teens to low-20s percentage points. Rapid benefits verification shortens time-to-therapy and lowers initiation friction. Tailored resources reduce therapy abandonment, which can exceed 25% for specialty drugs without support.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDifferentiated tolerability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDifferentiated tolerability emphasizes safety profiles optimized for chronic CNS therapy, minimizing cognitive and systemic burden to support adherence. Robust labeling and REMS-style guidance help clinicians manage common adverse events with clear titration and monitoring protocols. Real-world switch and stability data are provided to demonstrate maintained efficacy and tolerability, enabling broader patient eligibility with fewer treatment trade-offs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLong-term CNS safety focus\u003c\/li\u003e\n\u003cli\u003eClear AE management guidance\u003c\/li\u003e\n\u003cli\u003eReal-world switch\/stability data\u003c\/li\u003e\n\u003cli\u003eExpanded patient eligibility, fewer trade-offs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvidence for payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSupernus offers robust 2024 HEOR and budget-impact models and real-world outcomes showing up to 25% fewer hospitalizations and estimated per-patient annual savings up to $1,200, supporting payer value claims. Prior authorization templates and criteria alignment streamline access, and improved adherence reduces total cost of care via fewer exacerbations and downstream services.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHEOR models: budget-impact \u0026amp; ROI\u003c\/li\u003e\n\u003cli\u003eReal-world: ≤25% hospitalization reduction (2024)\u003c\/li\u003e\n\u003cli\u003ePA templates: criteria-aligned\u003c\/li\u003e\n\u003cli\u003eCost impact: ≈$1,200 saved\/PY (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnce-daily therapy cuts seizures, boosts adherence ~25% and saves ≈$1,200\/yr\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConsistent once-daily controlled-release therapy reduces seizure frequency and breakthrough events, improving patient-reported function; pivotal and real-world data show significant seizure reductions and ~25% higher adherence vs multi-dosing. HUB services accelerate starts (benefit verification 24–48h) and raise persistence by mid-teens pp. HEOR\/real-world models show up to 25% fewer hospitalizations and ≈$1,200 annual per-patient savings.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eSource (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence uplift\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003ctd\u003eMeta-analyses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBenefit verification\u003c\/td\u003e\n\u003ctd\u003e24–48h\u003c\/td\u003e\n\u003ctd\u003eHUB data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitalization reduction\u003c\/td\u003e\n\u003ctd\u003e≤25%\u003c\/td\u003e\n\u003ctd\u003eReal-world\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePer-patient savings\u003c\/td\u003e\n\u003ctd\u003e≈$1,200\/yr\u003c\/td\u003e\n\u003ctd\u003eHEOR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHCP engagement \u0026amp; education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProvide dedicated field medical support, accredited CME content, and practical clinical tools to HCPs, ensuring balanced, evidence-based interactions that reference pivotal trials and real-world evidence. Offer interactive dosing calculators and stepwise titration guides to streamline therapy decisions. Maintain responsive medical information channels (24\/7) for timely, data-driven answers to clinical queries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient \u0026amp; caregiver programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatient and caregiver programs streamline onboarding, offer co-pay assistance and automated refill reminders via multilingual digital touchpoints (web, app, SMS), improving adherence and reducing abandonment. Clear escalation pathways connect patients to case managers or specialty pharmacies when access barriers arise. Continuous feedback loops capture satisfaction and outcomes to refine services and resource allocation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePayer collaboration centers on regular evidence and utilization reviews, pairing outcomes-based discussions where appropriate to align value with reimbursement. Efforts focus on streamlined prior authorization and step-edit alignment to reduce administrative friction and speed patient access. Contract management emphasizes transparent reporting to support trust and measurable performance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKOL \u0026amp; advisory boards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKOL and advisory boards deliver structured input on study designs and publications, provide early insights on unmet needs and practice patterns, and advocate for guideline inclusion; long-term relationships anchor Supernus credibility and facilitate uptake.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStructured study and publication input\u003c\/li\u003e\n\u003cli\u003eEarly unmet-need insights\u003c\/li\u003e\n\u003cli\u003eGuideline advocacy\u003c\/li\u003e\n\u003cli\u003eLong-term credibility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-market safety \u0026amp; RWE\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSupernus maintains active pharmacovigilance with ongoing registry participation and quarterly safety updates to regulators and clinicians, publishing annual real-world evidence studies to support clinical decisions and label optimization.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eActive AE surveillance and registry engagement\u003c\/li\u003e\n\u003cli\u003eQuarterly safety updates and risk-mitigation plans\u003c\/li\u003e\n\u003cli\u003eAnnual RWE publications to inform prescribing\u003c\/li\u003e\n\u003cli\u003eContinuous benefit-risk optimization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e\n\u003cstrong\u003e24\/7\u003c\/strong\u003e med support and programs raise \u003cstrong\u003e30%\u003c\/strong\u003e co-pay uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDedicated field medical support, CME and tools cite pivotal trials and 2024 RWE; 24\/7 medinfo and dosing calculators aid HCP decision-making. Patient programs (30% co-pay assistance uptake in 2024) automate refills, multilingual outreach, and case manager escalation. Payer engagements cut prior-authorization time ~25%; KOLs and quarterly safety\/RWE reports sustain uptake and trust.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient support\u003c\/td\u003e\n\u003ctd\u003eCo-pay uptake\u003c\/td\u003e\n\u003ctd\u003e30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccess\u003c\/td\u003e\n\u003ctd\u003ePA time reduction\u003c\/td\u003e\n\u003ctd\u003e25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedinfo\u003c\/td\u003e\n\u003ctd\u003eAvailability\u003c\/td\u003e\n\u003ctd\u003e24\/7\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty sales to CNS HCPs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialty sales target neurologists, pediatric neurologists, and psychiatrists via in-office and virtual engagements customized to practice workflows, with virtual visits—now ~15% of behavioral health encounters in 2024—used for follow-ups and education. Territory planning is data-driven (claims, e-prescribing, CRM) to prioritize high-prescribing clusters and optimize rep deployment. All interactions are strictly compliance-focused, documented and auditable to meet regulatory requirements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty pharmacy network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialty pharmacy network leverages pharmacies experienced in CNS therapies to manage prior authorizations, REMS when applicable, and adherence support, improving persistence through targeted counseling. Data exchanges on fills and outcomes inform inventory and outcomes; specialty medicines comprised 54% of 2024 global drug spend (IQVIA), underscoring financial impact. Patient counseling boosts persistence, with specialty pharmacy adherence rates commonly reported near 75–85%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital platforms \u0026amp; portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHCP portals deliver resources, samples, and ePA tools to support prescribing, leveraging EHR interoperability as 96% of US physicians used EHRs (ONC 2023); patient apps provide education and adherence reminders with push engagement rates often \u0026gt;25%; webinars and on-demand CME expand reach—CME market ~3B in 2024—while analytics (real‑time KPIs, A\/B testing) refine content and targeting to lift conversion and adherence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical conferences \u0026amp; journals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePresent pivotal and RWE findings at top congresses (AAN, ACR, ASH) reaching \u0026gt;10,000 attendees to maximize exposure; Phase III programs typically enroll 500–1,500 patients and RWE cohorts often exceed 5,000 patient-years. Peer-reviewed articles and meta-analyses correlate with 10–30% higher clinician uptake. Booth engagement and sponsored symposia drive lead capture; structured post-event follow-up converts awareness into prescribing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConference reach: \u0026gt;10,000 attendees\u003c\/li\u003e\n\u003cli\u003eTrial scale: 500–1,500 pts\u003c\/li\u003e\n\u003cli\u003eRWE: \u0026gt;5,000 patient-years\u003c\/li\u003e\n\u003cli\u003eUptake lift from publications: 10–30%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributor \u0026amp; wholesaler links\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDistributor and wholesaler links ensure Supernus products reach \u0026gt;90% of US pharmacies via national wholesalers in 2024, with a 98% target fill rate and 48-hour order-to-ship SLA to optimize order flow and forecasting, plus defined RMA\/cold-chain protocols for sensitive products to manage returns and temperature-controlled integrity during transit.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCoverage: \u0026gt;90% US pharmacies (2024)\u003c\/li\u003e\n\u003cli\u003eFill rate target: 98% (2024)\u003c\/li\u003e\n\u003cli\u003eSLA: 48-hour order-to-ship\u003c\/li\u003e\n\u003cli\u003eCold-chain \u0026amp; RMA protocols enforced\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReps + specialty pharmacies drive \u0026gt;90% coverage, 98% fill and 75–85% adherence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSpecialty reps target neurologists, pediatric neurologists and psychiatrists with in-office and virtual visits (~15% of behavioral health encounters in 2024) using data-driven territory planning. Specialty pharmacies manage PA\/REMS and drive adherence (75–85%). Distributors reach \u0026gt;90% US pharmacies with 98% fill target and 48‑hr SLA.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVirtual visits\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty med spend\u003c\/td\u003e\n\u003ctd\u003e54%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacy coverage\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill rate target\u003c\/td\u003e\n\u003ctd\u003e98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurologists \u0026amp; psychiatrists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeurologists and psychiatrists are primary prescribers for epilepsy (≈3.4M US), ADHD (≈6.1M children diagnosed) and Parkinson’s disease (≈1M US). They prioritize clear efficacy, tolerability, and ease of use when selecting therapies. They value concise guidelines and support tools and drive adoption across care networks, influencing formulary and referral patterns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients \u0026amp; caregivers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIndividuals living with CNS conditions—about 3.4 million Americans with epilepsy—plus roughly 53 million US family caregivers need accessible, affordable, manageable therapies. Adherence for chronic diseases averages around 50% in high-income countries, making education and adherence support critical. These patients and caregivers advocate strongly for treatments that improve daily functioning and quality of life.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers \u0026amp; PBMs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePayers, PBMs and MCOs—with the top three PBMs managing ~75% of U.S. prescription claims in 2024—control access and formulary placement. They demand robust clinical-economic dossiers and real-world comparative-effectiveness data to justify coverage against constrained budgets. Utilization controls (prior authorization, step therapy) shape uptake and materially influence net pricing and coverage breadth, especially as specialty drugs account for ~50% of drug spend despite \u0026lt;2% of scripts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals \u0026amp; IDNs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHospitals and IDNs deliver acute and chronic CNS care across over 6,000 US hospitals as of 2024, prioritizing formulary access, standardized protocols, and smooth inpatient-to-outpatient transitions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFormulary influence: protocols and P\u0026amp;T committees\u003c\/li\u003e\n\u003cli\u003eSupply reliability: critical for inpatient continuity\u003c\/li\u003e\n\u003cli\u003eEconomic evidence: drives formulary inclusion and contracting\u003c\/li\u003e\n\u003cli\u003eCare coordination: outpatient continuation of therapy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacies \u0026amp; distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cppharmacies and distributors dispense therapies through retail specialty channels managing inventory patient counseling adherence programs while interfacing with payers for prior authorizations. in drugs drove roughly of us drug spend despite prescriptions community pharmacies filled about billion annually supplying critical utilization data back to manufacturers.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChannels: retail + specialty\u003c\/li\u003e\n\u003cli\u003eOperations: inventory, counseling, adherence\u003c\/li\u003e\n\u003cli\u003ePayer interface: prior auths, claims\u003c\/li\u003e\n\u003cli\u003eData: utilization feedback to Supernus\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/ppharmacies\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinicians, patients and payers align on tolerability, adherence and economic evidence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNeurologists\/psychiatrists (epilepsy 3.4M, ADHD 6.1M children, Parkinson’s ~1M) drive prescribing and formulary influence; patients\/caregivers demand tolerable, adherence‑supportive therapies; payers\/PBMs (top3 ~75% claims) require economic and real‑world evidence; hospitals\/IDNs (~6,000) and pharmacies (4.3B rx\/year) control access and distribution.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey data (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrescribers\u003c\/td\u003e\n\u003ctd\u003eEpilepsy 3.4M; ADHD 6.1M kids; Parkinson’s ~1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\/PBMs\u003c\/td\u003e\n\u003ctd\u003eTop3 ~75% claims; specialty drugs ~55% spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProviders\/Pharmacies\u003c\/td\u003e\n\u003ctd\u003eHospitals ~6,000; 4.3B rx\/year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and preclinical spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D and preclinical spend covers discovery, screening and formulation work; Supernus reported $92.4M in R\u0026amp;D in 2024, driven by hit-to-lead and formulation optimization activities. Lab infrastructure and scientific talent consume roughly 18% of R\u0026amp;D (~$16.6M) for equipment and headcount. External GLP studies and specialty assays accounted for about $18M, while IP filing and maintenance costs were ~$3.1M in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical \u0026amp; regulatory costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical \u0026amp; regulatory costs for Supernus include site fees, patient recruitment and monitoring, biometrics\/CRO and data management (major CRO contracts; 2024 CRO market spend \u0026gt;$50B globally), regulatory submissions\/agency interactions (2024 FDA PDUFA fee ~ $3.2M) and post-approval commitments including pharmacovigilance systems and ongoing PV costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing \u0026amp; supply chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCMO contracts drive fixed and variable production costs with the global CMO market \u0026gt;$50B (2023), requiring multi-year commitments and capacity clauses to control margins and ensure supply.\u003c\/p\u003e\n\u003cp\u003eAPI procurement and QA\/QC account for large shares of COGS, with rigorous batch release testing and tech transfers plus scale-up validation to meet regulatory specs and reduce failed batches.\u003c\/p\u003e\n\u003cp\u003ePackaging, serialization (DSCSA track-and-trace in force since 2023), and logistics add traceability and cold-chain cost; redundancy across suppliers and dual-sourcing mitigates shortages and stockouts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales, marketing \u0026amp; access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpsales marketing access costs center on a fully loaded annual cost per field rep pharma benchmark plus ongoing training global congresses printed materials and digital campaigns absorb of commercial budgets hub services affordability programs run tens to hundreds dollars several thousand patient depending therapy complexity heor studies payer negotiations typically require for dossiers modeling.\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eField force comp: 150k per rep (2024 benchmark)\u003c\/li\u003e\n\u003cli\u003eMarketing mix: ~20% to digital \u0026amp; congresses\u003c\/li\u003e\n\u003cli\u003eHUB\/affordability: $100s–$3,000s per patient\u003c\/li\u003e\n\u003cli\u003eHEOR\/payer: $250k–$1M program cost\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/psales\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eG\u0026amp;A \u0026amp; infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eG\u0026amp;A \u0026amp; infrastructure costs at Supernus cover corporate functions, compliance and legal support for drug approvals and commercialization, plus IT systems, cybersecurity, and analytics that enable R\u0026amp;D and commercial decision-making; facilities, insurance, and maintenance for manufacturing and offices; and board, audit and external advisory fees.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCorporate functions \u0026amp; legal\u003c\/li\u003e\n\u003cli\u003eIT, cybersecurity, analytics\u003c\/li\u003e\n\u003cli\u003eFacilities \u0026amp; insurance\u003c\/li\u003e\n\u003cli\u003eBoard \u0026amp; audit expenses\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D leads 2024 costs - \u003cstrong\u003e$92.4M\u003c\/strong\u003e, CRO\/CMO and field reps add material spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D dominated costs: $92.4M in 2024 with ~$16.6M lab\/headcount, $18M external GLP and $3.1M IP. Clinical\/regulatory and CRO spend (PDUFA ~$3.2M) plus post‑approval PV are material. CMO\/API, QA\/QC and packaging\/logistics drive COGS and supply redundancy. Sales\/marketing and G\u0026amp;A (field rep ~$150k each, HEOR $250k–$1M) complete the cost base.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003e2024 ($)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e92.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExternal GLP\/CRO\u003c\/td\u003e\n\u003ctd\u003e18M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP\u003c\/td\u003e\n\u003ctd\u003e3.1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eField rep (per)\u003c\/td\u003e\n\u003ctd\u003e150k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNet product sales (Rx)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNet product sales (Rx) are Supernus primary revenue, driven by branded CNS therapies with 2024 net product sales of about $598 million, influenced by volume, price, and product mix; gross revenue is materially reduced by rebates, discounts and chargebacks, and adherence programs (patient support, REMS) help preserve durable prescription refill rates and lifetime value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalties from out-licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoyalties from out-licensing generate recurring, low-capital-intensity income by licensing IP or territories to commercial partners; in 2024 Supernus continued to leverage this model to monetize non-US rights. Tiered royalty structures tied to sales milestones align incentives and can materially scale upside as partner sales grow. Out-licensing extends reach into ex-US markets without direct commercial investment, preserving cash for R\u0026amp;D.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilestone payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMilestone payments from collaborations deliver upfronts and contingent cash tied to development, regulatory and sales thresholds, providing Supernus with non-dilutive funding in 2024. These payments align risk-sharing with partners by linking payouts to proof-of-concept, NDA approvals and commercial milestones. Such structures help preserve equity while accelerating program finance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCo-promotion \u0026amp; co-marketing fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCo-promotion and co-marketing agreements let Supernus share commercialization in targeted geographies or segments, using fee or profit-share structures—commonly in the industry 10–30% splits—to expand reach without duplicating sales forces. This approach enhances market coverage and accesses complementary customer bases around established neurology products such as Trokendi XR and Oxtellar XR.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eShared commercialization in targeted segments\u003c\/li\u003e\n\u003cli\u003eFee\/profit-share structures (industry ~10–30%)\u003c\/li\u003e\n\u003cli\u003eExpands coverage while avoiding duplicated costs\u003c\/li\u003e\n\u003cli\u003eAccess to complementary customer bases\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLifecycle \u0026amp; label expansion gains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLifecycle and label expansion drive revenue through new indications and formulations, while sNDAs extend market exclusivity and delay generic entry. Line extensions target adjacent patient groups to broaden uptake, and iterative formulations improve adherence and pricing power. These actions cumulatively raise asset ROI over time for Supernus.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRevenue uplift: new indications\/formulations\u003c\/li\u003e\n\u003cli\u003esNDAs: extended exclusivity\u003c\/li\u003e\n\u003cli\u003eLine extensions: adjacent patient groups\u003c\/li\u003e\n\u003cli\u003eOutcome: improved asset ROI over time\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2024 Net Rx Sales \u003cstrong\u003e$598M\u003c\/strong\u003e — Royalties, milestones and co‑promotion sustain growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNet product sales (Rx) drove 2024 revenue—about $598 million—after rebates\/discounts; adherence programs support refill rates. Royalties and out‑licensing generated recurring income from ex‑US deals. Milestone payments provided non‑dilutive cash tied to development and approvals. Co‑promotion and label expansions extended commercial runway.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product sales\u003c\/td\u003e\n\u003ctd\u003e$598M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\/Milestones\u003c\/td\u003e\n\u003ctd\u003eRecurring (undisclosed)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098545754460,"sku":"supernus-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/supernus-business-model-canvas.png?v=1781806882","url":"https:\/\/pestel-analysis.com\/products\/supernus-business-model-canvas","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}